China biotech: Licensing deals and the Biosecure Act
China’s biotech sector has become impossible for the global industry to ignore. Chinese companies are producing innovative drugs — particularly in oncology, obesity, and gene editing — that Western pharma is licensing at an accelerating pace. At the same time, the Biosecure Act and broader US-China tensions have reshaped how companies structure partnerships, manufacturing relationships, and clinical trial strategies. Hengrui, WuXi, and a wave of smaller biotechs are navigating a complex landscape of opportunity and restriction. Endpoints tracks the China biotech story from licensing megadeals and outbound drug pipelines to the regulatory and geopolitical forces shaping cross-border drug development.
Top Stories
Can a Chinese drugmaker become a big pharma company? Hengrui is testing the waters
China’s rise splits US biotech investors: Cash in, or counter?
Ignoring China's biotech industry is no longer an option. It's a recipe for disaster
China’s biotech market is staging a comeback that US biotech can only wish for
China's MGI sells US subsidiary Complete Genomics after Biosecure Act stalled ambitions
China biotech: Licensing deals and the Biosecure Act Feed
CMS seeks to close Medicare negotiation 'loophole'
Takeda builds case around leading orexin program with new Phase 3 data
Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout
FDA approves Merck's Welireg-Keytruda combo as adjuvant treatment for kidney cancer
Amgen and the FDA want two different outcomes for Tavneos. What will patients do?
Eli Lilly invests in startup Abridge for clinical trial recruitment
Private jets, wildfire relief and $23,000 internet: The 2025 oddities of biopharma executive pay
WuXi AppTec sues Pentagon in challenge over inclusion on Chinese military list
GSK took advantage of ASCO dip to get discount on Nuvalent
Sciwind has two Western partners for its obesity drug, but is open to more
Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec says
Here are biopharma’s 10 highest-paid scientists and doctors for 2025
Kardigan's $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO
Neion Bio lands $23M Series A to make proteins from chicken eggs
'Going for our own moonshot': Parabilis CEO on biotech's record IPO
Novartis and Orionis strike second molecular glue deal for $40M upfront
Biopharma’s golden parachutes: 12 execs who took in the biggest M&A windfalls of $35M+
Eli Lilly's claims data deadline may kick off new 340B fight
Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow
Who pays the best (and worst) in biopharma? A look at typical employee salaries
Post-Hoc Live: How much is everyone in biopharma getting paid?
WuXi AppTec added to Pentagon's list of companies linked to Chinese military
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B